Anaplastic Large Cell Lymphoma (ALCL) is a clinical and biological heterogeneous disease including systemic ALK positive and ALK negative entities. Whereas ALK positive ALCLs are molecularly characterized and readily diagnosed, specific immunophenotypic or genetic features to define ALK negative ALCL are missing, and their distinction from other T-cell non-Hodgkin lymphomas (T-NHLs) can be controversial. In recent years, great advances have been made in dissecting the heterogeneity of ALK negative ALCLs and in providing new diagnostic and treatment options for these patients. A new revision of the World Health Organization (WHO) classification promoted ALK negative ALCL to a definite entity that includes cytogenetic subsets with prognostic implications. However, a further understanding of the genetic landscape of ALK negative ALCL is required to dictate more effective therapeutic strategies specifically tailored for each subgroup of patients.

The heterogeneous landscape of ALK negative ALCL

Mereu, Elisabetta;Pellegrino, Elisa;Inghirami, Giorgio;Piva, Roberto
Last
2017-01-01

Abstract

Anaplastic Large Cell Lymphoma (ALCL) is a clinical and biological heterogeneous disease including systemic ALK positive and ALK negative entities. Whereas ALK positive ALCLs are molecularly characterized and readily diagnosed, specific immunophenotypic or genetic features to define ALK negative ALCL are missing, and their distinction from other T-cell non-Hodgkin lymphomas (T-NHLs) can be controversial. In recent years, great advances have been made in dissecting the heterogeneity of ALK negative ALCLs and in providing new diagnostic and treatment options for these patients. A new revision of the World Health Organization (WHO) classification promoted ALK negative ALCL to a definite entity that includes cytogenetic subsets with prognostic implications. However, a further understanding of the genetic landscape of ALK negative ALCL is required to dictate more effective therapeutic strategies specifically tailored for each subgroup of patients.
2017
8
11
18525
18536
http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=14503&path%5B%5D=46280
ALK negative; Anaplasticl large cell lymphoma; Molecular classification; Therapy; Humans; Lymphoma, Large-Cell, Anaplastic; Prognosis; Receptor Protein-Tyrosine Kinases; Oncology
Mereu, Elisabetta; Pellegrino, Elisa; Scarfã², Irene; Inghirami, Giorgio; Piva, Roberto
File in questo prodotto:
File Dimensione Formato  
Mereu 2017 oncotarget-08-18525.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 734.02 kB
Formato Adobe PDF
734.02 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1657812
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 23
social impact